Crizotinib in ALK-Positive Diffuse Large B-Cell Lymphoma: A Case Report
Abstract
null null Background null Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a distinct variant of DLBCL characterized by very aggressive clinical course with an estimated median survival of only 11.0 months. Crizotinib, an ALK inhibitor, has demonstrated impressive clinical efficacy in patients with alk-rearranged tumors. The potential role of Crizotinib in ALK-positive DLBCL has not been established yet. null...
Paper Details
Title
Crizotinib in ALK-Positive Diffuse Large B-Cell Lymphoma: A Case Report
Published Date
Sep 1, 2012
Journal
Volume
23
Pages
ix357 - ix358
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History